Pilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in patients receiving botulinum toxin therapy

European Journal of Neurology

Volumn 20, Issue 3, 2013, Pages 515-518

  Lungu, C ^a   Considine, E ^a   Zahir, S ^a   Ponsati, B ^b   Arrastia, S ^b   Hallett, M ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b BCN Peptides SA   (Spain)

Author keywords

Blepharospasm; Botulinum; Dystonia; Therapy; Topical

Indexed keywords

ACETYL HEXAPEPTIDE 8; BOTULINUM TOXIN A; BOTULINUM TOXIN B; HEXAPEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLEPHAROSPASM; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; JANKOVIC BLEPHAROSPASM RATING SCALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOM;

ADMINISTRATION, TOPICAL; ADULT; AGED; BLEPHAROSPASM; BOTULINUM TOXINS, TYPE A; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; MIDDLE AGED; NEUROMUSCULAR AGENTS; OLIGOPEPTIDES; PILOT PROJECTS; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25;

EID: 84873991195     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12009     Document Type: Article

References (12)

1. Jankovic J, Havins WE, Wilkins RB. Blinking and blepharospasm. Mechanism, diagnosis, and management. JAMA 1982; 248: 3160-3164.
2. Simpson DM, Blitzer A, Brashear A, et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70: 1699-1706.
3. Willis B, Eubanks LM, Dickerson TJ, Janda KD. The strange case of the botulinum neurotoxin: using chemistry and biology to modulate the most deadly poison. Angew Chem Int Ed Engl 2008; 47: 8360-8379.
4. Blanes-Mira C, Clemente J, Jodas G, et al. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci 2002; 24: 303-310.
5. Jankovic J, Kenney C, Grafe S, Goertelmeyer R, Comes G. Relationship between various clinical outcome assessments in patients with blepharospasm. Mov Disord 2009; 24: 407-413.
6. Lindeboom R, De Haan R, Aramideh M, Speelman JD. The blepharospasm disability scale: an instrument for the assessment of functional health in blepharospasm. Mov Disord 1995; 10: 444-449.
7. Naumann M, Albanese A, Heinen F, Molenaers G, Relja M. Safety and efficacy of botulinum toxin type A following long-term use. Eur J Neurol 2006; 13(Suppl. 4): 35-40.
8. Limotai N, Go C, Oyama G, et al. Mixed results for GPi-DBS in the treatment of cranio-facial and cranio-cervical dystonia symptoms. J Neurol 2011; 258: 2069-2074.
9. Grumelli C, Verderio C, Pozzi D, Rossetto O, Montecucco C, Matteoli M. Internalization and mechanism of action of clostridial toxins in neurons. Neurotoxicology 2005; 26: 761-767.
10. Ruiz MA, Clares B, Morales ME, Cazalla S, Gallardo V. Preparation and stability of cosmetic formulations with an anti-aging peptide. J Cosmet Sci 2007; 58: 157-171.
11. Eyelid hygiene for blepharitis. Insight 2011; 36: 24.
12. Hallett M. Blepharospasm: recent advances. Neurology 2002; 59: 1306-1312.